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Abstract 1 
Objectives: Klebsiella pneumoniae carbapenemases (KPCs) have been increasingly 2 
reported in the UK since 2003. We analysed patient and isolate data for KPC-positive 3 
bacteria confirmed by the national reference laboratory from UK laboratories, with the 4 
exception of the North-West England region, where the epidemiology has previously been 5 
studied, from August 2003 to August 2014. 6 
Methods: MICs were determined by BSAC agar dilution methodology. Carbapenem-7 
resistant isolates lacking imipenem/EDTA synergy were tested by PCR for blaKPC. Multi-8 
locus sequence typing and blaKPC sequencing was performed on a subset of isolates. 9 
Plasmid analysis was performed by transformation, PCR-based replicon typing and, in some 10 
cases, whole-plasmid sequencing. Patient data provided by the sending laboratories were 11 
reviewed.   12 
Results:  Two hundred and ten KPC-producing isolates were submitted from 71 UK 13 
laboratories outside North-West England, representing 160 patients. All were 14 
Enterobacteriaceae, predominantly K. pneumoniae (82%; 172/210), and most (91%; 15 
191/210) were obtained from hospitalised patients. Analysis of 123 isolates identified blaKPC-2 16 
(64%; 79/123), blaKPC-3 (27%; 33/123) and blaKPC-4 (9%; 11/123). Within K. pneumoniae, 17 
clonal group (CG) sequence type (ST) 258 was dominant (64%; 54/84), however 21 18 
unrelated STs were also identified. Plasmid analysis identified a diverse range of plasmids of 19 
at least 11 different replicon types, found in multiple STs and species. 20 
Conclusions:  KPC enzymes are increasingly detected in Enterobacteriaceae in the UK 21 
outside North-West England, despite a lack of reported outbreaks. K. pneumoniae CG258 22 
are the dominant hosts although plasmid spread also plays a significant role in dissemination 23 
of KPCs between other K. pneumoniae STs and enterobacterial species.  24 
  25 
Introduction 26 
Klebsiella pneumoniae carbapenemases (KPCs) were first identified in 1996 in a K. 27 
pneumoniae isolate obtained from a patient hospitalised in North Carolina, USA.1 Since then 28 
they have disseminated globally, predominantly among Enterobacteriaceae, although there 29 
are also reports of production by Acinetobacter spp. and Pseudomonas aeruginosa isolates 30 
in the Americas.2-4 They have been reported in all inhabited continents, with numerous 31 
outbreaks described, particularly in Greece, Israel, Italy, the USA and China.4 Many of these 32 
outbreaks are associated with an internationally-disseminated lineage of K. pneumoniae, 33 
sequence type (ST) 258, and other members of its clonal group (CG) CG258, which 34 
comprises ST258, its single locus variants (SLVs), such as ST512, and their SLVs.5 KPCs 35 
are typically found encoded within the Tn3-based transposon, Tn4401, of which there are 36 
five isoforms (a, b, c, d and e) as defined by insertions or deletions within a polymorphic 37 
region immediately upstream of the blaKPC gene.6  The first fully-sequenced KPC-encoding 38 
plasmid was an IncFIB/IncFIIK replicon type designated pKpQIL, from an ST258 isolate in 39 
Israel, and highly similar plasmids have since been found in several other countries.7-9 KPC 40 
has also been reported to be carried by plasmids of other replicon types including IncI2, 41 
IncN, IncL/M and IncX, though these seem to be less frequent hosts of its gene.10-12  42 
Most bacteria with KPC enzymes are multi-resistant, harbouring genes whose products 43 
compromise non-β-lactam antibiotics (e.g. aac(6’)-Ib, encoding resistance to 44 
aminoglycosides except gentamicin),13,14 resulting in a paucity of treatment options. The K. 45 
pneumoniae ST258 lineage usually remains susceptible only to colistin, gentamicin and 46 
tigecycline; however, there have been documented outbreaks of colistin-resistant K. 47 
pneumoniae ST258, thereby further reducing therapeutic options.15,16 48 
The first KPC enzyme in the UK was identified in 2003 and was found in an Enterobacter 49 
cloacae complex blood culture isolate from Scotland.17 The first K. pneumoniae ST258 50 
isolate was found in a urine specimen in 2007,18 also in Scotland and since then, numbers of 51 
KPC-producing isolates referred to Public Health England’s (PHE) Antimicrobial Resistance 52 
and Healthcare Associated Infections (AMRHAI) Reference Unit have risen sharply.4 Most 53 
(>95%) originate from hospitals in North-West England (defined as the counties of Cheshire, 54 
Cumbria, Greater Manchester, Lancashire and Merseyside) where an outbreak, centred in 55 
Manchester, has been ongoing since 2010, despite control efforts.4,19 In contrast with most 56 
international experience, this outbreak is polyclonal in nature and attributable to the 57 
horizontal spread of a pKpQIL-like plasmid amongst multiple strains of multiple species of 58 
Enterobacteriaceae.4,19 Similar polyclonal situations have been described recently in other 59 
countries, including Spain and Canada.20,21 60 
Here we describe the first 160 bacteria producing KPC enzymes referred to AMRHAI from 61 
infected or colonised UK patients outside the North-West of England. 62 
  63 
Materials and methods 64 
Bacterial isolates, identification and susceptibility testing 65 
Isolates had been submitted to PHE’s AMRHAI Reference Unit from laboratories across the 66 
UK (excluding the North West) between August 2003 and 12th August 2014 for investigation 67 
of ‘unusual’ resistance, including to carbapenems. They were identified using chromogenic 68 
agars [CHROMagar™ Orientation (CHROMagar, Paris, France) and Brilliance UTI (Oxoid, 69 
Basingstoke, UK)], API-20E tests (bioMeriéux SA, Marcy-l’Etoile, France) or, since August 70 
2012, by MALDI-ToF Mass Spectrometry (Bruker Microflex LT, Bruker Daltonik GmbH, 71 
Bremen, Germany).   72 
Antibiotic susceptibilities (MICs) were determined by the British Society for Antimicrobial 73 
Chemotherapy (BSAC) agar dilution22 using AMRHAI’s standard Gram-negative antibiotic 74 
panel, which includes ertapenem, meropenem and imipenem (with/without 320 mg/L EDTA 75 
to detect metallo-carbapenemase producers). MICs were interpreted using BSAC or 76 
EUCAST breakpoints.23,24  77 
 78 
Screening for KPC genes 79 
Isolates exhibiting raised cefotaxime and ceftazidime MICs with no significant clavulanic acid 80 
synergy, and resistance, based on EUCAST/BSAC criteria to one or more of imipenem, 81 
meropenem ertapenem, but lacking imipenem/EDTA synergy (≥8 fold potentiation of 82 
imipenem by 320 mg/L EDTA) were screened by in-house PCR for KPC genes,1 and/or with 83 
a commercial microarray (Check-Points CT102, Check-Points, Wageningen, The 84 
Netherlands).25 85 
 86 
Whole Genome Sequencing (WGS) 87 
Genomes were sequenced using the Nextera sample preparation method and the standard 88 
2 × 251-base sequencing protocols on a MiSeq instrument (Illumina, San Diego, CA, USA). 89 
Reads were assembled into contigs using VelvetOptimiser 90 
(http://bioinformatics.net.au/software.velvetoptimiser.shtml), with k-mer values from 55 to 75. 91 
Sequence types and plasmid replicon types were extracted in silico by BLASTn using 92 
reference sequences from (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) and 93 
http://pubmlst.org/plasmid/ databases. 94 
 95 
Multi-locus sequence typing (MLST) and sequencing of KPC alleles 96 
A subset of 123 isolates (100 K. pneumoniae, 16 E. cloacae complex, four Escherichia coli, 97 
two K. oxytoca and one Citrobacter freundii), geographically representative of submissions 98 
and selected from throughout the study period, were chosen for further analysis. Sequence 99 
types were determined for K. pneumoniae, E. cloacae complex and E. coli isolates by 100 
traditional multi-locus sequence typing (MLST)26-28 or inferred from WGS data. The blaKPC 101 
alleles were defined either by sequencing PCR amplicons as previously described1 or from 102 
analysis of WGS data. 103 
 104 
Plasmid transformation, replicon typing and plasmid sequencing 105 
Transformation of plasmids encoding KPC enzymes was attempted by electroporation using 106 
the subset of 123 isolates and E. coli Alpha-Select recipient cells (Bioline, London, UK). 107 
Transformants were selected on LB agar containing 100 mg/L ampicillin, and colonies were 108 
screened for blaKPC by PCR. A subgroup of 59 transformants was selected and subjected to 109 
WGS as above; selection was based on their geographical and temporal distribution, KPC 110 
alleles, species of origin and STs.  111 
Replicon typing of blaKPC plasmids was performed as described previously29,30 or was 112 
inferred from WGS data. 113 
 114 
Patient demographic information 115 
Patient data were obtained from the accompanying request forms sent with submissions 116 
from referring laboratories. A patient was categorized as ‘new’ if they were found to have 117 
KPC-positive isolates detected by AMRHAI for the first time and ‘known’ if KPC-positive 118 
isolates, irrespective of species, had previously been identified from the patient by AMRHAI. 119 
 120 
Data analysis 121 
Data were analysed using Microsoft Excel and Bionumerics software v6.1 (Applied Maths, 122 
Sint-Martens-Latem, Belgium). 123 
  124 
Results 125 
Demographics of patients affected and distribution 126 
During the study period, AMRHAI confirmed 210 KPC-positive isolates from outside of 127 
North-West England.  These were submitted by 71 UK laboratories and obtained from 160 128 
patients. Figure 1 illustrates the distribution of these isolates among ‘new’ and ‘known’ 129 
patients, and among submitting laboratories. The first three KPC-producing organisms, as 130 
previously reported,17 were E. cloacae isolates found in blood specimens from a single 131 
patient across consecutive years (one in 2003 and two in 2004) from Scotland. All were 132 
found to produce the KPC-4 variant. The first KPC-producing K. pneumoniae isolate was 133 
identified in 2007 in a blood specimen, also from Scotland.18 The numbers of ‘new’ patients 134 
increased significantly from 2008 onwards (Figure 1). 135 
KPC-producing isolates were submitted from laboratories across all 11 UK regions studied. 136 
The national distribution of affected patients, as ascertained by AMRHAI referrals, was as 137 
follows: England (n=124), Scotland (n=26), Northern Ireland (n=9) and Wales (n=1). The 138 
greatest number of affected patients was from the Yorkshire and the Humber region (n=39), 139 
followed by London (n=27) and the West Midlands (n=20). 140 
Most source patients were hospitalized (86%; 138/160), but a few were outpatients (4%; 141 
6/160) or in primary care (6%; 10/160), or were from patients in an unknown setting (4%; 142 
6/160). The mean patient age was 60.4 years and most were male (58%, 92/160). 143 
Foreign travel history was available for 51/160 (32%) patients. Of these, 19 patients had 144 
documented travel within the previous six months to: Greece (11/19), Italy (2/19), Bulgaria, 145 
Curaçao, India, Israel, Macedonia, and Saudi Arabia (one patient each). Four of these 19, 146 
with histories of travel to Curaçao, Greece, Israel and Italy, were known to have been 147 
hospitalised whilst abroad. Information on patient transfers between UK regions was very 148 
limited, however 5/160 (3%) patients were known to have had KPC-producing isolates 149 
submitted from hospitals across two UK regions. Four KPC-positive patients had previously 150 
been hospitalised in the North-West (Manchester) prior to KPC isolations in Wales, Northern 151 
Ireland and Yorkshire and the Humber (two patients), and one KPC-positive patient had 152 
previously been hospitalised in Yorkshire and the Humber prior to the East Midlands.  153 
Single KPC-producing isolates were referred from 125/160 (78%) patients and multiple 154 
isolates were referred from the remaining 35/160 (22%). Amongst the 35 patients with 155 
multiple KPC-producing isolates, six (17%) yielded KPC-producing isolates of different 156 
species or genera and 14 (40%) had KPC-producing isolates obtained from different 157 
anatomical sites; the KPC-positive isolates were referred over a period of <14 days in 19/35 158 
(54%) instances and over a period >6 months from just one patient. 159 
The date when the sample was taken was available for 89% (187/210) of isolates and the 160 
median duration between this date and the isolate being received at AMRHAI was 8 days 161 
(Range = 1-49 days). 162 
 163 
Microbiology 164 
All KPC-positive isolates were Enterobacteriaceae. The majority were K. pneumoniae (82%; 165 
173/210) followed by E. cloacae complex (11%; 24/210), E. coli (4%; 9/210), K. oxytoca (1%; 166 
3/210) and C. freundii (<1%; 1/210). 167 
If samples, rather than patients were considered as the denominator, most were taken in 168 
hospitals (91%; 191/210), but some were from general practice urines (5%; 11/210) and a 169 
few samples were from an unknown setting (4%; 8/210). The most frequently reported 170 
specimen types were urines (33%; 70/210), followed by screening swabs (24%; 50/210). 171 
Ten percent (21/210) of isolates were obtained from blood cultures or line tips, 13% (29/210) 172 
from tissue and fluid samples and 10% (21/210) from faeces (Table 1). 173 
 174 
KPC alleles and typing of the isolates 175 
The KPC variants were defined for 59% (123/210) of isolates, distributed throughout the 176 
entire collection period (2003-2014). Of these, 64% (79/123) were blaKPC-2, 27% (33/123) 177 
were blaKPC-3, and 9% (11/123) were blaKPC-4; no other variants were detected. Isolates 178 
harbouring blaKPC-2 were geographically scattered and included K. pneumoniae, E. cloacae 179 
complex, and E. coli. blaKPC-3-positive isolates were also geographically scattered, but were 180 
all K. pneumoniae. blaKPC-4 was found only in E. cloacae complex isolates from Scotland.  181 
 182 
Klebsiella pneumoniae 183 
One hundred of the 173 K. pneumoniae isolates were typed by MLST. After the exclusion of 184 
isolates exhibiting the same ST from single patients, 84 results remained for analysis. 185 
Almost two-thirds (64%; 54/84) belonged to the CG258, comprising isolates belonging to 186 
ST258 (n=41), ST512 (n=9), ST11 (n=3) and ST833 (n=1). Between 2007 and 2014, CG258 187 
isolates were submitted from 31 laboratories across all UK regions studied (10/11) except 188 
Wales; 54% (22/41) produced KPC-2 and the remaining 46% (19/41) produced KPC-3 189 
enzymes. One of the earliest ST258 isolates was obtained in 2008 and was from the urine of 190 
a patient previously hospitalised in Israel;18 another ST258 isolate was from a wound swab 191 
of a patient hospitalised in Greece in 2011. However, the first ST258 isolate, from 2007, 192 
came from a patient that had no foreign travel history. ST512 isolates were referred from six 193 
laboratories between 2008 and 2014 from three UK regions, and all produced KPC-3. One 194 
patient who had K. pneumoniae ST512 isolated from a sputum sample in 2012 had been 195 
hospitalised in Italy within the previous six months. ST11 isolates were submitted between 196 
2009 and 2011 from two laboratories in two UK regions. One patient, with an ST11 isolate 197 
from urine, had a history of travel to Curaçao where he had been hospitalised for two weeks 198 
and had undergone urinary catheterisation. The last member of the CG258, a single isolate 199 
of ST833, produced KPC-2 and the patient had no known history of travel. There were four 200 
outbreaks in hospitals across three regions caused by members of CG258; ST11 producing 201 
KPC-2 in 2 patients, ST512 producing KPC-3 in 3 patients, ST258 producing KPC-3 in 2 202 
patients, and ST258 producing KPC-2 in 3 patients. These outbreaks were over periods 203 
ranging from 1 week to 2 months.  204 
Thirty (36%) characterised isolates did not belong to CG258. Of these, five isolates belonged 205 
to ST661, were submitted from two laboratories, located in different regions between July 206 
2013 and May 2014 and produced KPC-2 enzyme. The remaining 25, from 16 laboratories, 207 
represented 20 different STs and produced either KPC-2 (24/25) or KPC-3 (1/25) (Figure 2). 208 
 209 
Enterobacter cloacae complex 210 
Sixteen of 24 E. cloacae complex isolates were typed by MLST. After the exclusion of 211 
isolates exhibiting the same sequence type from a single patient, 12 results remained for 212 
analysis. Eight isolates that were submitted from five laboratories in Scotland between 2003 213 
and 2013, belonged to ST171 and produced KPC-4 enzyme. The remaining four isolates 214 
were ST133 (two isolates from the same hospital), ST190 and ST56 (one isolate each), and 215 
all produced KPC-2. 216 
 217 
Escherichia coli 218 
Four of the nine E .coli isolates were typed by MLST and represented four unrelated 219 
sequence types: ST12, ST127, ST131 and ST744. All four produced the KPC-2 enzyme. 220 
 221 
Antibiotic susceptibility 222 
The MIC distributions of KPC-positive isolates are shown in Table 2. All isolates were 223 
resistant to ertapenem and most were resistant or non-susceptible to imipenem (98%; 224 
202/207) and meropenem (97%; 201/208). All meropenem MICs were above the EUCAST 225 
screening concentration (MICs >0.125 mg/L).  All members of the K. pneumoniae CG258 226 
were resistant to tobramycin and most were also non-susceptible or resistant to amikacin 227 
(89%; 57/64), however two-thirds were susceptible to gentamicin. By comparison, members 228 
of non-CG258 K. pneumoniae STs (n=36) were more often susceptible to all three 229 
aminoglycosides (61%, 86% and 64% were susceptible to tobramycin, amikacin and 230 
gentamicin respectively). Most non-K. pneumoniae isolates also were susceptible to all three 231 
aminoglycosides. All members of the CG258 were resistant or non-susceptible to 232 
ciprofloxacin, compared with 47% (17/36) of other K. pneumoniae STs and 62% (23/37) of 233 
all other species. Colistin resistance was observed in 26 K. pneumoniae isolates, of which 234 
belonged to CG258, three to three unrelated STs; the STs of the remaining 10 colistin-235 
resistant isolates were undetermined. Colistin MICs for resistant isolates ranged from 4-32 236 
mg/L (Table 2) and resistant isolates originated from laboratories/hospitals across six UK 237 
regions. Susceptibility to tigecycline was observed in 61% (125/205) of all isolates but only in 238 
48% (31/64) of CG258 isolates. 239 
 240 
Plasmid analysis 241 
Transformants expressing KPC enzymes were obtained for 90/123 (73%) of the subset of 242 
isolates chosen for further analysis. PCR-based replicon typing and whole genome 243 
sequencing were performed on 90/90 and 59/90 transformants, respectively. The data 244 
revealed the following replicon types; IncFIB/IncFIIK (n=49), IncN (n=17), IncFIIK (n=8), 245 
IncFIB (n=3), IncR (n=3), ColE-like (n=2), IncI2 (n=2), IncFIA (n=1), IncP-6 (n=1), IncX3 246 
(n=1), and three plasmids were of untypable replicon types. Most (80%; 39/49) plasmids with 247 
the IncFIB/IncFIIk replicon type were obtained from members of the CG258. Of the 59 that 248 
were sequenced, 30/35 IncFIB/IncFIIK plasmids exhibited >99% sequence identity to 249 
pKpQIL (GenBank Accession No. NC_014016).  250 
The sizes of the sequenced KPC plasmids ranged from ~13kb to ~224kb. In all sequenced 251 
plasmids the KPC genes were located within Tn4401 isoforms a, b, c or d (Table 3). All 252 
plasmids encoded variants blaKPC-2 or blaKPC-3 with the exception of the two ColE-like 253 
plasmids found in E. cloacae complex isolates from Scotland, which encoded blaKPC-4. Most 254 
of the plasmid replicon types were recovered from multiple UK regions (Table 3). Some KPC 255 
plasmids were also shown to carry a number of additional antibiotic resistance genes (Table 256 
3). 257 
  258 
Discussion 259 
This report reviews the first 160 recorded patients infected or colonised by KPC-positive 260 
bacteria in the UK, excluding the North West of England (which accounts for most cases), as 261 
ascertained from referrals to PHE’s AMRHAI Reference Unit. Isolates were submitted over 262 
an eleven-year period from August 2003 to August 2014, from laboratories across the UK. 263 
KPC-producing isolates were submitted from all UK regions over this study period. The 264 
majority of isolates were obtained from clinical specimens (133/210), and these were 265 
predominantly urine samples (70/133). All isolates were multi-resistant to antibiotics and 266 
exhibited non-susceptibility to at least one of the three carbapenems tested. The only 267 
antibiotics that retained relatively good levels of activity in vitro were colistin (87%), 268 
gentamicin (65%) and tigecycline (61%). The use of colistin as monotherapy against KPC-269 
producers has limitations due to its nephrotoxicity and neurotoxicity and also the danger of 270 
selecting for colistin-resistant mutants.31 The potential for expansion of colistin-resistant 271 
variants is evidenced by reports of outbreaks caused by colistin-resistant members of the 272 
ST258 clone.15,16 In this study we found 26 K. pneumoniae isolates that were resistant to 273 
colistin, most of these were members of CG258, and they were found in 10/11 UK regions. 274 
The use of tigecycline is limited by its inability to achieve high concentrations in the urine and 275 
blood, and is licensed for the treatment of complicated skin and skin structure infections, and 276 
complicated intra-abdominal infections.32 Several antibiotic combinations have been used for 277 
the treatment of infections caused by KPC-producing bacteria including: colistin with 278 
aminoglycosides/carbapenems/fluoroquinolones, tigecycline with aminoglycosides, and 279 
several beta-lactam and fluoroquinolone/aminoglycoside combinations.31,33 Such 280 
combination therapies have been shown to be more effective than monotherapy and are 281 
believed to reduce the likelihood of the development of resistant mutants.31,33 282 
Although travel history was available for just one-third of the patients, 11/51 had travelled to 283 
Greece in the previous six months, two had travelled to Italy and one had travelled to Israel, 284 
all of which have reported nationwide KPC outbreaks within their hospitals.4 One patient with 285 
a wound infection caused by K. pneumoniae ST258 had previously been hospitalised in 286 
Greece, where ST258 lineages have caused multiple outbreaks since 2007.4 Another patient 287 
had been hospitalised in Curaçao for a period of two weeks prior to isolation of KPC-positive 288 
K. pneumoniae in the UK.34 The KPC-2-producing K. pneumoniae ST11 isolated from his 289 
urine was most likely acquired in Curaçao, where he was catheterised.34,35  One of the 290 
patients who had travelled to and been hospitalised in Italy was found to have a KPC-3-291 
producing K. pneumoniae ST512 (CG258), which is reported to be a problematic clone in 292 
Italy, causing outbreaks in several hospitals.4,36 Whilst it is not possible to know conclusively 293 
where acquisition of the KPC-producing bacteria took place, it is clear that international 294 
travel continues to play a significant role in the importation of KPC-producing clones, and 295 
this has been illustrated in the worldwide spread of members of CG258.4   296 
The finding that four patients had KPC isolations in hospitals across two UK regions 297 
demonstrates that domestic travel and patient transfers may play a vital role in the 298 
dissemination of KPC-producing bacteria within the UK. This has the potential to be 299 
particularly problematic when one UK region has an ongoing outbreak (the North-West) and 300 
could conceivably result in the expansion of this outbreak.  301 
At the time of this study there were 22 known KPC variants (KPC-2 – KPC-23) identified 302 
(www.lahey.org/studies/) and only three variants were found here: KPC-2, KPC-3 and KPC-303 
4. KPC-2 and KPC-3 are the most common variants worldwide, and their genes are often 304 
harboured on pKpQIL and pKpQIL-like plasmids.9,37 We first identified KPC-4 in 2003, and 305 
this variant has recently also been found in the USA on IncL/M plasmids in both E. cloacae 306 
and S. marcescens, and enocded by an IncN plasmid in K. pneumoniae.10,11 In this study all 307 
of the KPC-4-producing isolates were E. cloacae complex ST171 and had been isolated in 308 
five laboratories in Scotland over a 10-year period (from 2003 to 2013). Sequencing 309 
identified ~13 kb ColE-like plasmids encoding blaKPC-4 in two of these isolates. Despite the 310 
long-term persistence of this KPC-4-producing clone, it has not caused recognised 311 
outbreaks and its KPC-encoding plasmid has not spread to other hosts.   312 
Although the worldwide dissemination of KPC-producing bacteria is substantially associated 313 
with a single clonal group (K. pneumoniae CG258), KPC enzymes have been found in 314 
numerous other K. pneumoniae sequence types and in other bacterial species.4,10  blaKPC 315 
have been recorded as carried by several plasmids of different incompatibility groups, 316 
including IncF, IncI2, IncN, IncL/M and IncX.10-12,37 Here we found KPC genes in four 317 
bacterial species and in 34 different sequence types, carried by at least 11 plasmid replicon 318 
types, suggesting that both plasmid spread and the mobility between plasmids plays an 319 
important role in the dissemination of KPC in the UK. Within CG258 alone we found at least 320 
8 different KPC plasmid replicon types, indicative of the success of this clonal group as a 321 
host of KPC plasmids. The observation that most plasmids were of the IncFIB/IncFIIK and 322 
highly homologous to pKpQIL show that pKpQIL-like plasmids are be dominant in the UK. 323 
There are numerous reports of outbreaks of KPC-producers from other countries,4,8,12,15 324 
associated particularly with members of CG258. We have shown here that K. pneumoniae 325 
ST258 is the dominant host of KPC enzymes in the UK outside of North-West England and 326 
that multiple UK hospitals have been challenged by the introduction of this successful clone 327 
and its close relatives since 2007. Nevertheless, to date there have been very few clusters of 328 
infections or colonisations caused by K. pneumoniae ST258 in the UK. Whether the lack of 329 
CG258 dissemination can be attributed to better screening and/or compliance with infection 330 
control practices in the UK is unknown, but this does underline the need for continued 331 
surveillance and for implementation of rigorous infection prevention and control measures.38 332 
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 Hospital Setting 
Species Urines Screening 
swabs 
Blood cultures 
and line tips 
Respiratory Tissue and 
fluid 
Faeces Not 
known 
GP urines Total 
C. freundii 0 1 0 0 0 0 0 0 1 
E. cloacae complex 7 0 4 2 4 2 0 3 22 
E. coli 4 1 0 0 0 2 0 1 8 
Klebsiella spp. 44 47 17 12 24 16 4 7 171 
Total 55 49 21 14 28 20 4 11 202 
          
 Unknown Setting   
Species Urines Screening 
swabs 
Blood cultures 
and line tips 
Respiratory Tissue and 
fluid 
Faeces Not 
known 
 Total 
E. cloacae complex 1 1 0 0 0 0 0  2 
E. coli 1 0 0 0 0 0 0  1 
Klebsiella spp. 2 1 0 0 1 0 1  5 
Total 4 2 0 0 1 0 1  8 
 
Table 1. Source and species for the KPC-positive isolates from different settings. 
 
 
 
 
 
 
   Number of Isolates with MIC (mg/L)  
Species/ST Antibiotic 
(range 
tested, mg/L) 
EUCAST 
breakpoints 
≤S/>R 
≤0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128 NA %S 
K. pneumoniae/CG258 (n=64) 
Ertapenem 
(0.125-16) 
≤0.5/>1 
       64a     0 
K. pneumoniae/other STs (n=36)        36a     0 
K. pneumoniae/NT (n=73)       2 69a    2 0 
K. oxytoca/NT (n=3)        3a     0 
E. cloacae complex (n=24)     1 4 3 16a     0 
E. coli (n=9)      1 2 6a     0 
C. freundii (n=1)        1a     0 
Total       1 5 7 195a    2 0 
K. pneumoniae/CG258 (n=64) 
Imipenem      
(0.06-128) 
≤2/>8 
       6 13 15 19 11   0 
K. pneumoniae/other STs (n=36)     1  1 20 5 1 7 1 3 
K. pneumoniae/NT (n=73)       1 11 23 18 11 7 2 0 
K. oxytoca/NT (n=3)        3       0 
E. cloacae complex (n=24)   1 1 2 5 1 8 3 1 2   13 
E. coli (n=9)        5 4       0 
C. freundii (n=1)                 1       0 
Total     1 1 3 6 24 71 42 32 27 3 2 
K. pneumoniae/CG258 (n=64) 
Meropenem 
(0.06-32) 
≤2/>8 
     1 5 5 53a      0 
K. pneumoniae/other STs (n=36)       5 12 19a      0 
K. pneumoniae/NT (n=73)      2 10 21 38a    2 0 
K. oxytoca/NT (n=3)        3       0 
E. cloacae complex (n=24)  1 1 4 1 1 10 2 4a      29 
E. coli (n=9)      3 4 1 1      0 
C. freundii (n=1)                 1       0 
Total    1 1 4 1 7 34 44 116a   2 3 
K. pneumoniae/CG258 (n=64) 
Amikacin         
(0.5-64) 
≤8/>16 
  1b 1  2 3 11 36 10a     11 
K. pneumoniae/other STs (n=36)   1b 12 11 3 4 4 1      86 
K. pneumoniae/NT (n=73)   1b 11 10 9 9 9 16 6a   2 55 
K. oxytoca/NT (n=3)      3         100 
E. cloacae complex (n=24)   2b 10 8 3 1        100 
E. coli (n=9)    1 3 2 1 2       78 
C. freundii (n=1)             1           100 
Total     5b 35 32 22 19 26 53 16a  2 54 
K. pneumoniae/CG258 (n=64) 
Gentamicin 
(0.125-32) 
≤2/>4 
  4 16 23 6 7 3 5a      67 
K. pneumoniae/other STs (n=36)  3 16 4   2 1 10a      64 
K. pneumoniae/NT (n=73)  2 15 18 6  4 1 25a    2 58 
K. oxytoca/NT (n=3)    1 2          100 
E. cloacae complex (n=24)  5 11 3 1    4a      83 
E. coli (n=9)   2 2 2 1   2a      67 
C. freundii (n=1)                 1a       0 
Total    10 48 44 34 7 13 5 47a   2 65 
K. pneumoniae/CG258 (n=64) 
Tobramycin 
(0.125-32) 
≤2/>4 
       9 55a      0 
K. pneumoniae/other STs (n=36)  3 15 3 1 1  5 8a      61 
K. pneumoniae/NT (n=73)  3 15 5 1   7 40a    2 34 
K. oxytoca/NT (n=3)    2  1         67 
E. cloacae complex (n=24)  3 12 4 1   1 3a      83 
E. coli (n=9)   2 1 4    2a      78 
C. freundii (n=1)                 1a       0 
Total    9 44 15 7 2  22 108a   2 36 
K. pneumoniae/CG258 (n=64) 
Ciprofloxacin 
(0.125-8) 
≤0.5/>1 
      64a        0 
K. pneumoniae/other STs (n=36) 15b 1 3 3   14a        53 
K. pneumoniae/NT (n=73) 15b 1 1 3 2 2 47a      2 24 
K. oxytoca/NT (n=3) 3b              100 
E. cloacae complex (n=24) 1b 1 4 2 1 2 13a        25 
E. coli (n=9) 2b 2 1    4a        56 
C. freundii (n=1)             1           0 
Total   36b 5 9 8 3 4 143a     2 7 
K. pneumoniae/CG258 (n=64) 
Colistin            
(0.5-32) 
≤2/>2 
  38b 11 1  3  10a    1 79 
K. pneumoniae/other STs (n=36)   21b 12   2 1       92 
K. pneumoniae/NT (n=73)   50b 10 1 2 2  6a    2 86 
K. oxytoca/NT (n=3)   2b 1           100 
E. cloacae complex (n=24)   18b 6           100 
E. coli (n=9)   3b 6           100 
C. freundii (n=1)       1                 100 
 
S, susceptible; R, resistant; NA, not available; NT, not typed; CG, clonal group; ST, sequence type. 
Cells highlighted in dark grey are resistant; those in light grey are intermediate; and white are susceptible. 
aMIC greater than or equal to indicated value.  
bMIC less than or equal to the indicated value. 
 
Table 2. MIC distributions for KPC-producing isolates (n=210). 
 
 
 
 
 
 
 
Total     132b 47 2 2 7 1 16a   3 87 
K. pneumoniae/CG258 (n=64) 
Tigecycline   
(0.25-16) 
≤1/>2 
  4 27 27 6         48 
K. pneumoniae/other STs (n=36)  3b 12 12 8 1         75 
K. pneumoniae/NT (n=73)   11 29 20 4 4 3a     2 56 
K. oxytoca/NT (n=3)  1b 2            100 
E. cloacae complex (n=24)   7 9 2 1 2      3 76 
E. coli (n=9)  6b 1 1 1          89 
C. freundii (n=1)         1               0 
Total    10b 37 78 59 12 6 3a    5 61 
 Figure 1. Numbers of new and known affected patients and laboratories sending KPC-
positive isolates per quarter during the study period. 
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 Figure 2. Minimum spanning tree of the MLST profiles of 84 KPC-positive K. pneumoniae 
isolates, received between September 2007 and July 2014 from 65 submitting laboratories. 
The shaded areas represent members of the ST258 clonal group. Members of the ST258 
clonal group are labelled, as are other STs with >4 submissions. The diameter of the circle 
represents the number of isolates of that particular ST. Thick solid lines represent single-
locus variants; thin solid lines represent double-locus variants, and the absence of 
connecting lines indicates multi-locus variants
ST258 
 
ST661 
 
 
ST11 
ST512 
ST833 
 Replicon 
Types 
No. of 
Plasmids 
Approx. 
Size (kb) 
Species KPC 
Variants 
Other resistance 
genes 
STs* carrying 
plasmids 
No. of 
Regions 
Tn4401 
Isoform(s) 
ColE-like 2 13 E. cloacae 
complex 
KPC-4  171 1 a 
IncFIA 1 52 K. 
pneumoniae 
KPC-2 blaTEM-1, blaOXA-9 15 1 a 
IncFIB 1 76 K. 
pneumoniae 
KPC-3 blaTEM-1, blaOXA-9 258 1 a 
IncFIIK 3 97 - 213 K. 
pneumoniae 
KPC-2 blaTEM-1, blaOXA-9, 
aadA2, aadA5, dfrA12, 
dfrA17, catA1, sul, 
mph(A), qnrB1  
258/321/1162 3 a 
IncFIB/IncFIIK 35 106 - 
224 
K. 
pneumoniae 
KPC-2/3 blaTEM-1, blaOXA-9, 
aadA2, aadA5, dfrA12, 
dfrA17, catA1, sul, 
mph(A), qnrB1 
15/147/252/258/307/3
21/512/ 
678/709/732/896/116
2/1163 
7 a 
IncI2 2 77 K. 
pneumoniae 
KPC-3 blaOXA-9, blaTEM-1, 
aac(6')-Ib, aadA1 
258 1 b 
IncN 8 59 - 76 K. 
pneumoniae/
K. oxytoca 
KPC-2 blaTEM-1, blaTEM-135, 
aph(6)-Id, sul, dfrA, 
qnrB2 258/336/1026 
4 b/c 
IncR 3 48 - 69 K. 
pneumoniae 
KPC-2/3 aac(6')-Ib, aadA2, 
catA1, cmlA1, mef(B) 
258 2 a/b 
IncX3 1 53 K. 
pneumoniae 
KPC-3 blaTEM-1, qnrB2, aph(6)-
Id, sul, dfrA 
258 1 a 
IncP-6 1 38 K. 
pneumoniae 
KPC-2 blaTEM-33 11 1 a 
Untypable 2 62 - 89 K. 
pneumoniae 
KPC-2/3 blaTEM-1, blaOXA-9, 
aph(6)-Id, aac(6')-Ib, 
aadA1, qnrB2, aph(6)-
Ib, sul, dfrA 
258/833 2 b/d 
 
Table 3. The features of 59 KPC plasmids sequenced.*STs were determined for K. pneumoniae and E. cloacae complex isolates. 
